<DOC>
	<DOCNO>NCT02528682</DOCNO>
	<brief_summary>Allogeneic stem cell transplantation ( allo-SCT ) potent treatment , sometimes curative treatment aggressive hematological malignancy . The therapeutic efficacy attribute graft-versus-tumor ( GVT ) response , donor-derived CD8+ T cell become activated recipient minor histocompatibility antigen ( MiHA ) present dendritic cell ( DC ) . Consequently , alloreactive donor T cell clonally expand , acquire effector function kill MiHA-positive malignant cell . However , substantial number patient persistence recurrence malignant disease observe , indicate insufficient GVT immunity induce . This reflected observation patient develop productive CD8+ T cell response towards MiHA mismatch recipient donor . We find PD-1/PD-L1 co-inhibitory pathway involve dampen MiHA-specific CD8+ T cell expansion function post-transplantation . Therefore , promise strategy induce boost GVT immune response pre-emptive therapeutic vaccination ex vivo-generated donor DCs load MiHA exclusively express recipient hematopoietic cell malignant counterpart . In contrast pre-emptive donor lymphocyte infusion ( DLI ) polyclonal donor T cell , MiHA-DC vaccination approach less risk induce graft-versus-host disease ( GVHD ) potency induce efficient GVT-associated T cell immunity . In addition , potency DC vaccine enhance interference PD-1/PD-L1 co-inhibitory pathway , use siRNA mediate PD-L1/PD-L2 silencing .</brief_summary>
	<brief_title>MiHA-loaded PD-L-silenced DC Vaccination After Allogeneic SCT</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Patients AML , myelodysplasia ( MDS ) , ALL , CML ( accelerate blast phase ) , CLL , MM malignant NHL , underwent HLAmatched alloSCT Patients positive HLAA2 and/or HLAB7 Patients positive HA1 , LRH1 and/or ARHGDIB transplant correspond MiHAnegative donor Patients â‰¥18 year age WHO performance 02 Witnessed write informed consent Life expectancy &lt; 3 month Severe neurological psychiatric disease Progressive disease need cytoreductive therapy HIV positivity Patients acute GVHD grade 3 4 Patients severe chronic GVHD Patients active infection ( viral , bacterial fungal ) require specific therapy . Acute antiinfectious therapy must complete within 14 day prior study treatment Severe cardiovascular disease ( arrhythmias require chronic treatment , congestive heart failure symptomatic ischemic heart disease ) Severe pulmonary dysfunction Severe renal dysfunction ( serum creatinine &gt; 3 time normal level ) Severe hepatic dysfunction ( serum bilirubin transaminase &gt; 3 time normal level ) Patients known allergy shell fish</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>dendritic cell</keyword>
	<keyword>PD-L1/L2 silencing</keyword>
	<keyword>vaccination</keyword>
	<keyword>stem cell transplantation</keyword>
	<keyword>minor histocompatibility antigen</keyword>
</DOC>